Printer Friendly

'BIOTECH MONITOR' LAUNCHES INDUSTRY'S FIRST INDEPENDENT INVESTMENT AUDIT

'BIOTECH MONITOR' LAUNCHES INDUSTRY'S FIRST INDEPENDENT INVESTMENT AUDIT
 NEW YORK, Sept. 9 /PRNewswire/ -- William S. Doyle, president of Strategic Marketing Systems, Inc., announced the formation of the New York City-based company today and its mission to "transfer marketing technology" to biotechnology from other industries. "As an investor in biotech," Doyle said, "I want to expand the tools biotech companies use for increasing their share value and ability to raise capital."
 Strategic Marketing Systems' first product is the "Biotech Monitor(R)," the first of its kind, independent annual audit of how the key 100 institutional investors, financial analysts, fund managers and brokers rate and perceive biotech companies. The study will be limited to 20 corporations and begins in November.
 To ensure complete objectivity of the research and analysis, the study will be conducted by an independent and respected market research company, Consumer Behavior, Inc. This will protect the findings from the biases and subjectivity inherent in surveys conducted in-house or by direct suppliers.
 "We want to introduce the same research based discipline to help biotech companies market themselves that the biotech companies use to invent their own products," said Doyle. Doyle is the founder of the Ecomarine group of companies and was formerly the director of worldwide marketing at Chase Manhattan Bank in New York, after successive management posts with the bank in London and Hong Kong. Strategic Marketing Systems is located at 885 Third Avenue, New York, N.Y. 10022, telephone, 212-230-2177.
 -0- 9/9/92
 /CONTACT: William S. Doyle of Strategic Marketing Systems, 212-230-2177/ CO: Strategic Marketing Systems, Inc. ST: New York IN: SU: PDT


PS -- NY085 -- 7701 09/09/92 17:06 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 9, 1992
Words:275
Previous Article:NEED FOR TRUCKS REMAINS CRITICAL IN HURRICANE DISASTER AREAS
Next Article:RJR NABISCO $750 MILLION NOTES RATED 'BBB' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
Audit Bureau of Circulations Launches First Ad Campaign in 83 Years
Merrill Lynch Introduces Single Security Representing 20 Biotech Stocks.
Independent Monitoring Council Completes Initial and Follow-Up Audits of Mattel Plant in Mexico.
Health Pathways(TM) Introduces Audit Services Division; A Due Diligence Process to Protect U.S. Pharmaceutical Distribution System Integrity Against...
monitorforhire.com Exceeds 1,500 Clinical Monitor Registrations Becoming the World's Largest Web-Based Provider of Independent Clinical Monitors;...
Health Products Research Reports on 2004 Promotional Activities to Hematology and Oncology Specialists;.
Independent Data Monitoring Board Recommends that GPC Biotech Continue Satraplatin Phase 3 Trial as Planned.
Independent Data Monitoring Board Recommends That Satraplatin Phase 3 Trial Continue as Planned.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters